#United States #San Francisco #J.P. Morgan #Viking Therapeutics #VKTX

Viking Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Viking Therapeutics, Inc., a formidable name in the biopharmaceutical realm, is gearing up for its appearance at the prestigious 43rd Annual J.P. Morgan Healthcare Conference. Slated for January 13-16, 2025, this conference will take place at the iconic Westin St. Francis in San Francisco, California, and promises to shine a spotlight on cutting-edge advancements in healthcare and therapeutics.

Scheduled to present is the dynamic CEO Dr. Brian Lian, who will share insights into Viking's innovative approach and groundbreaking research aimed at tackling metabolic and endocrine disorders. His corporate presentation is set for January 13, 2025, from 1:30 to 2:10 PM Pacific Time. This event serves as a unique platform for investors and stakeholders to gain an in-depth understanding of the company's strategic direction and potent therapeutic candidates.

Viking Therapeutics is focused on developing novel therapies that stand out in their field, having three compounds currently in clinical development stages. Among these is VK2735, a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This innovative candidate aims to address various metabolic disorders, leveraging comprehensive clinical trial data that showcases its promising safety profile and efficacy in improving patient outcomes.

Additionally, there’s VK2809, a highly progressive small molecule designed specifically for the treatment of metabolic disorders and non-alcoholic fatty liver disease. Viking's recent trials demonstrated VK2809's significant effectiveness, achieving key endpoints in both Phase 2 studies for biopsy-confirmed NASH and NAFLD, signaling a major step forward in therapeutic options.

Furthermore, the company is exploring the potential of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other related disorders, indicating Viking's commitment to addressing multiple aspects of metabolic diseases with innovative solutions.

In the realm of rare diseases, Viking is developing VK0214, another promising candidate aimed at treating X-linked adrenoleukodystrophy (X-ALD). Results from early trials have shown VK0214's safety and its ability to effectively reduce harmful plasma lipid levels, demonstrating its potential to significantly improve patient lives.

For those unable to attend, a live webcast of Dr. Lian's presentation will be accessible from the Viking Therapeutics website, ensuring that the latest information reaches a broad audience. A replay will also be made available following the conference, emphasizing Viking's approach to transparency and outreach during such critical engagements.

Viking’s dedication to improving the lives of patients with metabolic and endocrine disorders positions it as a leader in the field. As they prepare for the J.P. Morgan conference, the anticipation builds for what could be a turning point in their journey towards developing life-changing therapies. For continuous updates on their progress and initiatives, interested parties are encouraged to visit their official website at www.vikingtherapeutics.com.

In summary, Viking Therapeutics is not only paving the way with its clinical advancements but is also actively engaging with the investment community at one of the healthcare industry's most significant events. With promising assets in its pipeline and a commitment to enhancing patient care, Viking is a company worth watching closely as it continues to unfold its therapeutic narrative in 2025 and beyond.